OLEMA PHARMACEUTICALS, INC. Debt Securities, Available-for-sale
OLEMA PHARMACEUTICALS, INC. (OLMA) had Debt Securities, Available-for-sale of $461.17 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale $461.17M.
- 2026-03-31: Debt Securities, Available-for-sale $505.50M.
- 2025-12-31: Debt Securities, Available-for-sale $505.64M.
- 2025-09-30: Debt Securities, Available-for-sale $329.07M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $461.17M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $505.50M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $505.64M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $329.07M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $362.00M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $392.87M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $434.74M 10-K · filed 2026-03-16 |
| 2024-09-30 | $214.86M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $239.23M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $249.18M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $262.11M 10-K · filed 2025-03-18 |
| 2023-09-30 | $277.24M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $167.53M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $186.01M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $204.54M 10-K · filed 2024-03-11 |
| 2022-09-30 | $222.62M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $240.73M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $267.87M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $287.25M 10-K · filed 2022-02-28 |
| 2021-09-30 | $305.95M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $318.14M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $326.97M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |